Novo-backed Procept BioRobotics has secured series G funding to further commercialise its surgical robotic system.
Procept BioRobotics, a US-based surgical robotic technology developer backed by pharmaceutical firm Novo, received $85m on Wednesday in a series G round led by investment and financial services group Fidelity.
Fidelity was joined by investment manager T Rowe Price Associates and investment firms CPMG and Viking Global Investors, in addition to hedge fund manager Perceptive Advisors and Duquesne Family Office.
Founded in 2009, Procept sells an automated surgical robotic system used in a minimally invasive urologic surgery known as aquablation…
